tapebrief
UHS · Q2 2025
Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

UHS · Q3 2025 Earnings

Universal Health Services

Reported October 28, 2025

30-second summary

UHS posted Q3 revenue of $4.50B (+13.4% YoY) and non-GAAP EPS of $5.69, with adjusted EBITDA margin net of NCI at 14.9%, and raised FY25 guidance across revenue, EBITDA, and EPS for the second consecutive quarter. The EPS midpoint moved from $20.50 to $21.80 — a $1.30 (+6.3%) lift — driven by a $90M Columbia DC supplemental payment expected in Q4, Cedar Hill tracking to Q4 breakeven (vs. prior expectation of losses through year-end), and acute pricing running at +9.8% per adjusted admission (same facility). Behavioral volume remains the soft spot but is improving (+1.3% same-facility patient days vs. +1.2% last quarter), and management framed labor-driven volume constraint as resolving.

Headline numbers

EPS

Q3 FY2025

$5.69

Revenue

Q3 FY2025

$4.50B

+13.4% YoY

Operating margin

Q3 FY2025

11.6%

Key financials

Q3 FY2025
MetricQ3 FY2025YoYQ2 FY2025QoQ
Revenue$4.50B+13.4%$4.28B+4.9%
EPS$5.69—$5.35+6.4%
Operating margin11.6%—11.7%-10bps

Guidance

UHS raised full-year FY2025 guidance across all major metrics—revenue, adjusted EPS, and EBITDA—signaling stronger operational momentum and volume improvements heading into Q4.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
Revenue
FY2025
$17.096 billion to $17.312 billion$17.306 billion to $17.445 billion+$0.210B to +$0.133B (low to high end)Raised
Adjusted EPS (non-GAAP)
FY2025
$20.00 to $21.00 per share$21.50 to $22.10 per share+$1.50 to +$1.10 (low to high end)Raised
Adjusted EBITDA, net of NCI
FY2025
$2.458 billion to $2.543 billion$2.569 billion to $2.619 billion+$0.111B to +$0.076B (low to high end)Raised

Segment KPIs

Q3 FY2025
SegmentQ3 FY2025YoY
Acute Care Services$2.63B+16.7%
Behavioral Health Care Services$1.865B+12.4%

Other KPIs

Q3 FY2025
SegmentQ3 FY2025
Adjusted Admissions (Acute Care, same facility)2.0% growth YoY
Adjusted Patient Days (Acute Care, same facility)0.4% growth YoY
Revenue Per Adjusted Admission (Acute Care, same facility)9.8% growth YoY
Revenue Per Adjusted Patient Day (Acute Care, same facility)11.5% growth YoY
Adjusted Admissions (Behavioral Health, same facility)0.5% growth YoY
Adjusted Patient Days (Behavioral Health, same facility)1.3% growth YoY
Adjusted EBITDA Margin (net of NCI)14.9%
Debt / Adjusted EBITDA (net of NCI, LTM)1.86x

Management tone

Narrative arc: Q2 cautious tone with sized 2028 cliff → Q3 bullish reframe with execution wins stacking.

Three quarters ago Cedar Hill was framed as a multi-quarter open-ended drag awaiting Medicare certification; last quarter management sized it at $50M of 2025 EBITDA with profitability pushed to 2026; this quarter it's a Q4 breakeven story heading into 2026 as a tailwind. Management's language — "we achieved accreditation in early September... we expect to exit this year at break even or better, putting us in a stronger position at this facility heading into 2026" — converts what had been the single largest named operational headwind into a base for 2026 contribution. This is the most consequential tone shift in the print because it removes the dominant Street modeling overhang and re-rates the de novo execution narrative.

Behavioral outpatient was a sidebar in prior quarters and is now positioned as a structural growth engine. Management disclosed a Thousand Branches brand, dedicated outpatient personnel reorganized throughout the company, and 10 step-in programs opening in 2025 — "we've reorganized such that throughout the organization now there's really dedicated personnel... that are dedicated outpatient focused." The shift from tactical capacity additions to org-wide reorganization signals management views this as the structural answer to the behavioral volume problem, not a sidebar.

Behavioral volume framing shifted from "labor scarcity with uncertain resolution" to "expected to reach 2–3% growth exiting 2025." Management cited "our hiring numbers are increasing incrementally" and "hiring trends have improved steadily throughout the year." Adjusted patient days at +1.3% supports the trajectory but doesn't yet prove the inflection — this is the highest-conviction bull case and also the most easily falsified by the next print.

On acute pricing, management is now more openly framing revenue cycle gains as persistent rather than transient. Steve described "some revenue cycle initiatives that we've undertaken to ensure that our billing is clean and complete, that our denial appeals are as appropriate and aggressive as they should be, dispute resolutions with a number of payers" as adding ~$5 per admission of core pricing on top of the historical 3% — i.e., the +9.8% reported run-rate is no longer being characterized as a transitory mix or DPP artifact. This is a notable shift; last quarter the framing was that 3% was sustainable with excess seen as discrete.

OB3 quantification was refined upward: $420–470M cumulative net benefit reduction by 2032 (vs. $360–400M last quarter), now with a defined endpoint. Management hedged this as "subject to change potentially by material amounts" but the larger number reflects recent supplemental program approvals expanding the base being eroded — paradoxically, both the near-term tailwind and the long-term drag grew.

Recurring themes management leaned on this quarter:

Medicaid supplemental program expansion ($1.3B full-year 2025 benefit; DC $90M in Q3 alone)Behavioral outpatient acceleration as strategic pivot (Thousand Branches, step-in model, 10 programs opening in 2025)De novo hospital ramp-up (Cedar Hill approaching profitability, West Henderson performing ahead of expectations, Palm Beach Gardens on track for spring 2026)Acute care pricing strength from revenue cycle maturation ($5 per admission core pricing vs 3% historical)Behavioral volumes stabilizing as labor market tightness eases (hiring improvements, 1.3% APD growth Q3 with 2-3% target)Capital allocation prioritization: share buybacks and dividends over M&A in near term ($1.5B new buyback authorization, $1.759B total)

Risks management surfaced:

OB3 legislation reducing net supplemental benefit $420-470M annually starting 2028 through 2032 (subject to state-by-state interpretation uncertainty)Exchange subsidy expiration risk ($50-100M estimated impact, trending toward higher end due to volume growth)Behavioral managed care utilization management continuing to constrain length of stay and patient routingLas Vegas tourist volume decline potentially rippling into broader economic weakness and unemployment riseNorth Carolina Medicaid behavioral rate cuts (though noted as immaterial to UHS at 2% of behavioral beds)

Answers to last quarter's watch list

Cedar Hill Joint Commission survey outcome and Medicare certification date. Accreditation achieved early September; financial drag began subsiding in Q3; management expects Q4 break-even or better and Cedar Hill as a 2026 tailwind. This was the single most important watch item and resolved decisively in the bull direction.
Resolved positively
Behavioral same-facility adjusted patient days. Came in at +1.3% vs. Q2's +1.2% — directionally up but still below the 2–3% management target. Management forecasts further volume improvement in Q4 and 2–3% growth exiting 2025/into 2026 on the back of improved hiring. The inflection thesis is being asserted but not yet shown in the print.
Continue monitoring
Behavioral pricing ex-Tennessee DPP. Management disclosed same-facility behavioral revenue +9.3% YoY (+8.5% ex-DC supplemental), with per-adjusted-admission pricing +8.8% and per-adjusted-day +7.9% (+7.1% ex-DC). Without a clean ex-Tennessee cut, the durability of underlying pricing is still harder to fully triangulate, but the ex-DC normalization shows the underlying run-rate remains high-single-digit. Status: Partially resolved
Additional state DPP program approvals. The DC Columbia supplemental program ($90M Q4 collection, contributing to $1.3B full-year 2025 supplemental benefit) is the named addition this quarter, on top of Tennessee. The DPP cadence is delivering and remains the primary near-term tailwind.
Resolved positively
FY25 guide trajectory at Q3. Raised again. Revenue midpoint $17.20B → $17.38B; EBITDA midpoint $2.50B → $2.59B; EPS midpoint $20.50 → $21.80 (+6.3%). This is the second consecutive raise and the largest of 2025.
Resolved positively

What to watch into next quarter

Behavioral same-facility adjusted patient days print in Q4. Management has explicitly committed to a 2–3% exit rate. Q4 actual below +2% would directly contradict the labor-resolution narrative; +2% or better validates the outpatient/step-in reorganization as a real volume driver and is the cleanest test of the bull case.

Cedar Hill Q4 EBITDA disclosure. Management said "break even or better." Any disclosed positive contribution in Q4 sets a stronger 2026 base; a slip back into the red would force a reset on the de novo execution narrative.

FY26 initial guidance framing. With Cedar Hill flipping to a tailwind, DC supplemental annualizing, and acute pricing run-rate at +9.8%, the question is whether management guides FY26 EPS materially above the FY25 $21.80 midpoint or anchors conservatively given exchange subsidy expiration risk ($50–100M estimated impact, trending higher).

Acute revenue per adjusted admission run-rate. Management is now framing the +$5/admission revenue cycle uplift as persistent. Watch whether Q4 holds above +7% (well above the historical 3% core) or reverts — the answer recasts the durability of acute margins.

2028 OB3 mitigation specificity. The cumulative drag was bumped to $420–470M by 2032. With $1.3B of 2025 supplemental benefit and an OB3 bite of ~33% of that by 2032, watch the Q4 call for any new mitigation specifics (additional state DPPs, AI cost takeout, non-Medicaid behavioral capacity) — generalities here will increasingly draw skepticism.

Capital return cadence. $1.759B total buyback authorization with leverage at 1.86x and management explicitly prioritizing buybacks/dividends over M&A. Watch the Q4 pace — anything below the recent run-rate would suggest management is reserving capacity for an M&A pivot or sees more macro caution than the guide implies.

Sources

  1. UHS Q3-2025 press release, exhibit 99.1: https://www.sec.gov/Archives/edgar/data/352915/000119312525252399/uhs-ex99_1.htm
  2. UHS Q3-2025 earnings conference call (commentary referenced in tone section; transcript excerpts as cited)
  3. UHS Q2-2025 brief (Tapebrief) for prior-quarter guide and watch list comparison

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.